2hats
Dust.
For completeness, the top line 'third dose' booster results from Pfizer/BioNTech for standard dose (30µg) BNT162b2 administered around 11 months after the original standard two-dose series, which were announced yesterday.
These are the first results from their randomised, controlled COVID-19 vaccine booster trial (<10k participants, 16+ years), which demonstrated a relative vaccine efficacy of 95.6% (95%CI:89.3-98.6) to disease occurrence (during a period when delta/B.1.617.2 was dominant), consistent irrespective of age, sex, race, ethnicity, or comorbidity.
Note that the efficacy quoted is disease reduction in the boosted vaccinees relative to unboosted (ie original two-dose series only) vaccinees (all of who had no prior infection), and not relative to unvaccinated persons.
Related, a small study of BNT162b2 booster neutralisation of early wild-type, beta/B.1.351 and delta B.1.617.2 (23 US vaccinees, 18-85 years, in a randomised, placebo-controlled, phase 1–2–3 pivotal trial), that supports the above results. Here the 30µg booster was administered around 8-9 months after the original standard two-dose series. Immunoresponses more akin to that of hybrid immunity, with significant increases in neutralising immunity substantially greater than that following the original second dose, were observed.
DOI: 10.1056/NEJMc2113468.
These are the first results from their randomised, controlled COVID-19 vaccine booster trial (<10k participants, 16+ years), which demonstrated a relative vaccine efficacy of 95.6% (95%CI:89.3-98.6) to disease occurrence (during a period when delta/B.1.617.2 was dominant), consistent irrespective of age, sex, race, ethnicity, or comorbidity.
Note that the efficacy quoted is disease reduction in the boosted vaccinees relative to unboosted (ie original two-dose series only) vaccinees (all of who had no prior infection), and not relative to unvaccinated persons.
Pfizer and BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine | Pfizer
First results from any randomized, controlled COVID-19 vaccine booster trial demonstrate a relative vaccine efficacy of 95.6% against disease during a period when Delta was the prevalent strain In trial with more than 10,000 participants 16 years of age and older, COVID-19 booster was found to...
www.pfizer.com
Related, a small study of BNT162b2 booster neutralisation of early wild-type, beta/B.1.351 and delta B.1.617.2 (23 US vaccinees, 18-85 years, in a randomised, placebo-controlled, phase 1–2–3 pivotal trial), that supports the above results. Here the 30µg booster was administered around 8-9 months after the original standard two-dose series. Immunoresponses more akin to that of hybrid immunity, with significant increases in neutralising immunity substantially greater than that following the original second dose, were observed.
DOI: 10.1056/NEJMc2113468.
Last edited: